Pharm Exec5d
Biogen, Stoke Therapeutics Ink Deal to Develop Zorevunersen for Dravet Syndrome
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
PMLiVE6d
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...
pharmaphorum5d
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...
The Pharma Letter2d
The week in pharma: action, reaction and insight – week to February 21
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
American Association of Individual Investors5d
Which Is a Better Investment, Biogen Inc. or Insmed Incorporated Stock?
Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...
Barchart on MSN2d
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%
Generally, a “Strong Buy” rating on Wall Street indicates that analysts believe the stock will appreciate and outperform the ...
pharmaphorum3d
Biogen go quantum to speed up drug development
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.